We came across a bullish thesis on Genmab A/S on Gabriel Koh’s Substack. In this article, we will summarize the bulls’ thesis on GMAB. Genmab A/S’s share was trading at $33.87 as of January 13th. GMAB’s trailing and forward P/E were 14.83 and 12.58, respectively according to Yahoo Finance.
Photo by National Cancer Institute on Unsplash
Genmab is a leading biotechnology company focused on antibody therapeutics for cancer and serious diseases, operating a royalty driven, asset light...
